News | 17 August 2012
NEW YORK (AP) ? Shares of Vivus Inc. stumbled Friday after an analyst slashed his sales estimates for Vivus' new obesity drug Qsymia, saying many physicians may prescribe Qsymia's ingredients for their patients instead of the drug itself. THE SPARK: ...
Click on the link to read the full article at Businessweek
(This link will open in a new window)